Is there a Bearish outlook for Geron Corporation (NASDAQ:GERN) this week?

June 14, 2018 - By Jason Grubb

Geron Corporation (NASDAQ:GERN) LogoInvestors sentiment increased to 1.19 in Q1 2018. Its up 0.26, from 0.93 in 2017Q4. It increased, as 12 investors sold Geron Corporation shares while 30 reduced holdings. 22 funds opened positions while 28 raised stakes. 58.68 million shares or 0.06% less from 58.72 million shares in 2017Q4 were reported.
Art Limited Liability Co, New York-based fund reported 148,700 shares. Creative Planning holds 0% or 208,103 shares in its portfolio. 12,407 are held by Zeke Capital Ltd Liability Co. Moreover, Bnp Paribas Arbitrage has 0% invested in Geron Corporation (NASDAQ:GERN). Fin Architects owns 2,050 shares. 10,000 were accumulated by Sns Fin Group Ltd Limited Liability Company. Bankshares Of America De invested in 308,418 shares or 0% of the stock. 14,287 were reported by Prudential Fincl. Federated Investors Pa has invested 0% of its portfolio in Geron Corporation (NASDAQ:GERN). Fernwood Investment Management has invested 0.04% in Geron Corporation (NASDAQ:GERN). Price T Rowe Associate Md accumulated 0% or 85,890 shares. State Of Wisconsin Investment Board holds 110,000 shares or 0% of its portfolio. 138,882 are owned by State Board Of Administration Of Florida Retirement Sys. Moreover, Legal And General Gp Public Ltd Liability Co has 0% invested in Geron Corporation (NASDAQ:GERN). Ubs Asset Mgmt Americas owns 95,648 shares.

Geron Corporation (NASDAQ:GERN) Ratings Coverage

Among 2 analysts covering Geron Corp (NASDAQ:GERN), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Geron Corp has $7.0 highest and $4.0 lowest target. $5.50’s average target is 43.98% above currents $3.82 stock price. Geron Corp had 2 analyst reports since March 18, 2018 according to SRatingsIntel. The firm has “Hold” rating given on Sunday, March 18 by Stifel Nicolaus. The company was maintained on Monday, March 19 by Piper Jaffray. Below is a list of Geron Corporation (NASDAQ:GERN) latest ratings and price target changes.

19/03/2018 Broker: Piper Jaffray Rating: Buy New Target: $7.0 Maintain
18/03/2018 Broker: Stifel Nicolaus Rating: Hold New Target: $4.0 Maintain

The stock increased 2.41% or $0.09 during the last trading session, reaching $3.82. About 2.94 million shares traded. Geron Corporation (NASDAQ:GERN) has risen 56.15% since June 14, 2017 and is uptrending. It has outperformed by 43.58% the S&P500.

Geron Corporation operates as a biopharmaceutical company. The company has market cap of $661.17 million. The firm supports the clinical stage development of a telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It currently has negative earnings. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses.

More important recent Geron Corporation (NASDAQ:GERN) news were published by: Seekingalpha.com which released: “Making The Bull Case For Geron: Understanding The Risk/Reward Of Telomerase Biology” on May 18, 2018, also Globenewswire.com published article titled: “Geron Announces Oral Presentation at European Hematology Association Congress”, Seekingalpha.com published: “Key events next week – healthcare” on June 08, 2018. More interesting news about Geron Corporation (NASDAQ:GERN) was released by: Seekingalpha.com and their article: “Geron: Beware Shorts Slinging Bull (Longs Do It Too)” with publication date: May 25, 2018.

Geron Corporation (NASDAQ:GERN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: